[Clinical studies on flomoxef in respiratory infection].
Clinical efficacy, bacteriological effect and safety of a new antibiotic flomoxef (FMOX, 6315-S) in respiratory infections were studied. Efficacy of FMOX in 6 patients with infectious diseases including 2 cases with pneumonia, 3 cases with acute exacerbation by respiratory infection, 1 case with obstructive pneumonia were clinically evaluated. Two strains of Haemophilus influenzae, 1 strain of Streptococcus pneumoniae and 1 strain of Staphylococcus aureus which were detected as causative organisms in 2 cases disappeared or decreased after treatment with FMOX. Assessing both clinical and bacteriological findings, effects of FMOX were good in 5 cases and fair in 1 case. No adverse effects were observed in clinical or laboratory findings. Consequently, FMOX is considered to be a very useful antibiotic in the treatment for respiratory infectious diseases.
Yoshida
M
M
Second Department of Internal Medicine, School of Medicine, Fukuoka University.
Miyahara
S
S
Aritomi
T
T
Seki
M
M
Ishibashi
M
M
D000328:Adult; D000368:Aged; D001419:Bacteria / Q000302:isolation & purification; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D002511:Cephalosporins; C045693:flomoxef